23results about "Mucins" patented technology

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The present invention relates to a purified, biocompatible mucus, which has the ability to form a gel. The mucus of the invention may be provided in a tissue model, with a cell population. The mucin or tissue model of the invention may be useful in an in vitro model of digestion, mucus permeation and / or epithelial transport.

An oligonucleotide comprising a lipophilic monomer and a use thereof in non-liver delivery. Specifically, the present disclosure relates to an oligonucleotide, comprising an antisense strand complementary to a target gene, a sense strand complementary to the antisense strand, and one or more compounds represented by formula (I). The present disclosure further relates to a pharmaceutical composition comprising the oligonucleotide, and a medicinal use of the oligonucleotide and / or the pharmaceutical composition.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

Provided herein are compositions, methods, and uses relating to antibodies that immunospecifically bind to glycosylated forms of MUC16, a tethered mucin. Also provided herein are uses and methods for managing, treating, or preventing a disease, e.g., cancer.

The present disclosure relates to chimeric Tim receptors, host cells modified to contain chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present disclosure relates to oligonucleotides comprising lipophilic monomers and their use in non-liver delivery. Specifically, the present disclosure relates to oligonucleotides comprising an antisense strand complementary to a target gene, a sense strand complementary to the antisense strand, and one or more compounds represented by formula (I). The present disclosure further relates to pharmaceutical compositions comprising the oligonucleotides, and pharmaceutical uses of the oligonucleotides and / or pharmaceutical compositions.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

Described herein are synthetic glycopolypeptides that contain sugars identified as active in mucin. These compounds reduce the virulence of high-priority opportunistic pathogens, including, but not limited to, Salmonella enterica subsp. enterica serovar Typhimurium, Candida albicans, and Gardnerella vaginalis, without reducing the viability of beneficial Lactobacillus crispatus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

An anti-tumor fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein may contain protein MBP and protein MUC1-N. An amino acid sequence of the fusion protein is set forth in SEO ID NO.3. The fusion protein can be used for the prevention and / or treatment of pancreatic cancer.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

An anti-tumor fusion protein, which can inhibit MUC1-positive tumor cell growth and can inhibit pancreatic cancer tumor cell growth, has broad application prospects for the prevention and / or treatment of pancreatic cancer.

Provided are compositions and methods related to modified lubricin, methods of making the modified lubricin, and methods of using the modified lubricin to coat a variety of inanimate articles and to prevent and / or treat conditions in which enhanced lubrication of one or more parts of a human or non-human mammal is desired.

An anti-tumor fusion protein, wherein the fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein has broad application prospects for the prevention and / or treatment of pancreatic cancer.

Disclosed are synthetic mucins comprising homopolymers or copolymers of sugar and amino acid building blocks that mimic the structure and function of naturally-occurring mucins. Methods for their synthesis involve ring-opening polymerization of sugar-amino acid conjugate monomers, optionally together with amino acid monomers or derivatives serving as spacers or crosslinkers, followed by deprotection steps to yield tailored polymers with controlled sequence, molecular weight, and functionality. Compositions containing these synthetic mucins have utility in pharmaceutical, cosmetic, biomedical, and industrial applications such as lubricants, adhesives, moisturizers, protective coatings, and mucus substitutes.